Portfolio Holdings Detail for ISIN IE0009QS7W62
Stock Name / FundMSCI Wld Hlth US A
Issuer
Entity holding fund iShares V Public Limited Company
Entity Type
Entity LEI 549300QETNU1W5JY7Z94
ETF TickerWHCA(EUR) Euronext Amsterdam

Holdings detail for NBIX

Stock NameNeurocrine Biosciences Inc
TickerNBIX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS64125C1099
LEI549300FECER0XBN49756

Show aggregate NBIX holdings

News associated with NBIX

Wednesday's ETF with Unusual Volume: FLSP
The Franklin Systematic Style Premia ETF is seeing unusually high volume in afternoon trading Wednesday, with over 1.1 million shares traded versus three month average volume of about 30,000. Shares of FLSP were up about 0.5% on the day. Components of that ETF with the highest - 2025-04-16 16:12:59
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Royal Bank of Canada
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities research analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a $137.00 price objective on the stock, down from their prior price objective of $138.00. […] - 2025-04-16 05:56:51
UBS Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $137.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock. A number of other analysts have also weighed in on NBIX. Royal Bank of Canada cut their target price […] - 2025-04-07 05:38:48
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $165.38 Consensus Price Target from Brokerages
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on […] - 2025-04-03 06:06:54
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by American Century Companies Inc.
American Century Companies Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 49.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,523 shares of the company’s stock after selling 88,727 shares during the period. American Century Companies […] - 2025-04-02 07:54:55
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Corient Private Wealth LLC
Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,927 shares of the company’s stock after purchasing an additional 3,094 shares during the quarter. Corient Private […] - 2025-03-27 09:14:52
Envestnet Portfolio Solutions Inc. Purchases 278 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,868 shares of the company’s stock after acquiring an additional 278 shares […] - 2025-03-27 09:14:51
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $184.00 at JPMorgan Chase & Co.
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $183.00 to $184.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock. Several other research analysts also recently commented on NBIX. Barclays increased their price objective on Neurocrine Biosciences from […] - 2025-03-27 07:47:06
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday. A number of other analysts have also recently issued reports on NBIX. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences […] - 2025-03-14 06:12:43
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by M&T Bank Corp
M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company’s stock after buying an additional 1,322 shares during the quarter. […] - 2025-03-12 08:19:05
Victory Capital Management Inc. Sells 14,309 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Victory Capital Management Inc. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 189,896 shares of the company’s stock after selling 14,309 shares during the period. Victory Capital Management […] - 2025-03-11 08:16:52
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 762,557 shares of the company’s stock after buying an additional 15,266 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $104,089,000 as […] - 2025-03-10 11:50:03
Smartleaf Asset Management LLC Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Smartleaf Asset Management LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 37.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 538 shares of the company’s stock after purchasing an additional 146 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Neurocrine Biosciences were worth $74,000 as of its […] - 2025-03-10 09:10:55
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by IFP Advisors Inc
IFP Advisors Inc raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,020 shares of the company’s stock after purchasing an additional 137 shares during the period. IFP Advisors Inc’s holdings […] - 2025-03-03 09:35:15
First Horizon Advisors Inc. Has $118,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 865 shares of the company’s stock after selling 142 shares during the period. First Horizon Advisors Inc.’s holdings in Neurocrine Biosciences were worth $118,000 at the end […] - 2025-02-27 09:05:01
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,442 shares of the company’s stock after selling 6,148 shares during the period. Vontobel Holding […] - 2025-02-19 09:15:16
Neurocrine Biosciences (NASDAQ:NBIX) Earns Hold Rating from Analysts at Deutsche Bank Aktiengesellschaft
Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Tuesday, MarketBeat reports. The brokerage issued a hold rating and a $138.00 target price on the stock. NBIX has been the subject of a number of other research reports. Needham & Company LLC restated a “hold” […] - 2025-02-14 09:04:49
State of Alaska Department of Revenue Cuts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,535 shares of the company’s stock after selling 200 shares during the quarter. State of Alaska Department […] - 2025-02-12 10:44:45
Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $169.20
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on […] - 2025-02-12 08:12:57
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. NBIX has been the subject of several other research reports. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from […] - 2025-02-11 07:12:48
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 4.9% After Analyst Downgrade
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report)’s share price traded down 4.9% on Monday after Guggenheim lowered their price target on the stock from $165.00 to $163.00. Guggenheim currently has a buy rating on the stock. Neurocrine Biosciences traded as low as $116.48 and last traded at $116.60. 1,568,535 shares changed hands during mid-day […] - 2025-02-11 06:10:42
Royal Bank of Canada Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $148.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock. A number of other research firms have also recently weighed in on NBIX. Canaccord Genuity Group lowered […] - 2025-02-10 16:58:49
Canaccord Genuity Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $163.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective trimmed by Canaccord Genuity Group from $172.00 to $163.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James restated an “outperform” rating and […] - 2025-02-10 16:58:47
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by abrdn plc
abrdn plc boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.8% during the fourth quarter, Holdings Channel reports. The firm owned 156,574 shares of the company’s stock after buying an additional 20,150 shares during the quarter. abrdn plc’s holdings in Neurocrine Biosciences were worth $21,372,000 at the end of […] - 2025-02-07 09:28:53
Notable ETF Outflow Detected - XBI, NBIX, ALNY, UTHR
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.4 million dollar outflow -- that's a 1.2% decrease week over week ( - 2025-02-05 16:06:35
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tokio Marine Asset Management Co. Ltd.
Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,183 shares of the company’s stock after selling 119 shares […] - 2025-02-05 10:54:50
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 96.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,634 shares of the company’s stock after selling 372,648 shares during the period. Robeco Institutional Asset Management […] - 2025-02-04 08:47:05
KBC Group NV Has $1.96 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
KBC Group NV lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 24.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 14,330 shares of the company’s stock after selling 4,642 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were […] - 2025-02-02 11:40:51

MSCI Wld Hlth US A NBIX holdings

DateNumber of NBIX Shares HeldBase Market Value of NBIX SharesLocal Market Value of NBIX SharesChange in NBIX Shares HeldChange in NBIX Base ValueCurrent Price per NBIX Share HeldPrevious Price per NBIX Share Held
2025-04-17 (Thursday)1,865USD 189,074USD 189,074
2025-04-16 (Wednesday)1,865USD 186,687NBIX holding increased by 7349USD 186,6870USD 7,349 USD 100.1 USD 96.1598
2025-04-15 (Tuesday)1,865USD 179,338NBIX holding increased by 2368USD 179,3380USD 2,368 USD 96.1598 USD 94.8901
2025-04-14 (Monday)1,865USD 176,970NBIX holding increased by 7497USD 176,9700USD 7,497 USD 94.8901 USD 90.8702
2025-04-11 (Friday)1,865USD 169,473NBIX holding increased by 280USD 169,4730USD 280 USD 90.8702 USD 90.7201
2025-04-10 (Thursday)1,865USD 169,193NBIX holding decreased by -8504USD 169,1930USD -8,504 USD 90.7201 USD 95.2799
2025-04-09 (Wednesday)1,865USD 177,697NBIX holding increased by 14435USD 177,6970USD 14,435 USD 95.2799 USD 87.5399
2025-04-08 (Tuesday)1,865USD 163,262NBIX holding decreased by -10649USD 163,2620USD -10,649 USD 87.5399 USD 93.2499
2025-04-07 (Monday)1,865USD 173,911NBIX holding decreased by -4476USD 173,9110USD -4,476 USD 93.2499 USD 95.6499
2025-04-04 (Friday)1,865USD 178,387NBIX holding decreased by -23611USD 178,3870USD -23,611 USD 95.6499 USD 108.31
2025-04-02 (Wednesday)1,865USD 201,998NBIX holding increased by 2443USD 201,9980USD 2,443 USD 108.31 USD 107
2025-04-01 (Tuesday)1,865USD 199,555NBIX holding decreased by -6714USD 199,5550USD -6,714 USD 107 USD 110.6
2025-03-31 (Monday)1,865USD 206,269NBIX holding decreased by -4774USD 206,2690USD -4,774 USD 110.6 USD 113.16
2025-03-28 (Friday)1,865USD 211,043NBIX holding decreased by -1567USD 211,0430USD -1,567 USD 113.16 USD 114
2025-03-27 (Thursday)1,865USD 212,610NBIX holding decreased by -839USD 212,6100USD -839 USD 114 USD 114.45
2025-03-26 (Wednesday)1,865USD 213,449NBIX holding decreased by -3227USD 213,4490USD -3,227 USD 114.45 USD 116.18
2025-03-25 (Tuesday)1,865NBIX holding increased by 22USD 216,676NBIX holding increased by 3625USD 216,67622USD 3,625 USD 116.18 USD 115.6
2025-03-24 (Monday)1,843USD 213,051NBIX holding increased by 6782USD 213,0510USD 6,782 USD 115.6 USD 111.92
2025-03-21 (Friday)1,843USD 206,269NBIX holding increased by 3410USD 206,2690USD 3,410 USD 111.92 USD 110.07
2025-03-20 (Thursday)1,843USD 202,859NBIX holding decreased by -442USD 202,8590USD -442 USD 110.07 USD 110.31
2025-03-19 (Wednesday)1,843USD 203,301NBIX holding increased by 1124USD 203,3010USD 1,124 USD 110.31 USD 109.7
2025-03-18 (Tuesday)1,843USD 202,177NBIX holding decreased by -3318USD 202,1770USD -3,318 USD 109.7 USD 111.5
2025-03-17 (Monday)1,843USD 205,495NBIX holding increased by 1383USD 205,4950USD 1,383 USD 111.5 USD 110.75
2025-03-14 (Friday)1,843USD 204,112NBIX holding increased by 3243USD 204,1120USD 3,243 USD 110.75 USD 108.99
2025-03-13 (Thursday)1,843USD 200,869NBIX holding decreased by -147USD 200,8690USD -147 USD 108.99 USD 109.07
2025-03-12 (Wednesday)1,843USD 201,016NBIX holding increased by 3410USD 201,0160USD 3,410 USD 109.07 USD 107.22
2025-03-11 (Tuesday)1,843USD 197,606NBIX holding decreased by -6727USD 197,6060USD -6,727 USD 107.22 USD 110.87
2025-03-10 (Monday)1,843USD 204,333NBIX holding decreased by -4000USD 204,3330USD -4,000 USD 110.87 USD 113.04
2025-03-07 (Friday)1,843NBIX holding decreased by -46USD 208,333NBIX holding decreased by -6730USD 208,333-46USD -6,730 USD 113.04 USD 113.85
2025-03-05 (Wednesday)1,889USD 215,063USD 215,063
2024-11-12 (Tuesday)2,441USD 310,031USD 310,031
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NBIX by for IE0009QS7W62

Show aggregate share trades of NBIX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-03-25BUY22 116.180* 110.75
2025-03-07SELL-46 113.040* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NBIX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-04-17457,575124678,13267.5%
2025-04-16965,3531681,358,85571.0%
2025-04-15379,4271,823668,18356.8%
2025-04-14450,911249754,05659.8%
2025-04-11333,520203674,09149.5%
2025-04-10472,023315628,44075.1%
2025-04-09602,3303041,006,29959.9%
2025-04-08436,875162790,24955.3%
2025-04-07674,3984211,003,46367.2%
2025-04-04539,933385892,09460.5%
2025-04-03376,70499768,73849.0%
2025-04-02234,959215551,49842.6%
2025-04-01280,10130636,76344.0%
2025-03-31216,215308411,40852.6%
2025-03-28265,01180324,52281.7%
2025-03-27234,01141308,20075.9%
2025-03-26305,665215394,49577.5%
2025-03-25314,22286480,62565.4%
2025-03-24273,4171,005391,30669.9%
2025-03-21332,9586436,52176.3%
2025-03-20210,69223342,21661.6%
2025-03-19175,55972288,22360.9%
2025-03-18202,506165360,59356.2%
2025-03-17212,919102305,43569.7%
2025-03-14163,94214,843330,86749.5%
2025-03-13178,6727,541288,43761.9%
2025-03-12201,638171467,32343.1%
2025-03-11231,365248763,18830.3%
2025-03-10214,090558359,05959.6%
2025-03-07251,5315,013472,74353.2%
2025-03-06224,16621423,94152.9%
2025-03-05159,7154,490349,12245.7%
2025-03-04307,911358727,57242.3%
2025-03-03222,56396471,07447.2%
2025-02-28237,037493383,82361.8%
2025-02-27211,618246374,16056.6%
2025-02-26220,080241366,56660.0%
2025-02-25272,3631561,03248.5%
2025-02-24365,2053,840564,43364.7%
2025-02-21445,671334788,12956.5%
2025-02-20243,050438387,17462.8%
2025-02-19169,7811,293322,57252.6%
2025-02-18243,796157366,50666.5%
2025-02-14365,65187,819568,41664.3%
2025-02-13289,466152469,42261.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.